country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-189211

Copy Link Print Information

NNRT-IN-17

NNRT-IN-17 is a non-nucleoside HIV-1 Reverse Transcriptase inhibitor with an IC₅₀ of 0.095 μM. NNRT-IN-17 exerts its inhibitory effect by binding to the NNRTI binding pocket and adjacent sites, and exhibits antiviral activity against wild-type and multiple NNRTI-resistant mutant strains. NNRT-IN-17 can be used for the study of HIV-1 infection (AIDS).

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Formule: C₃₁H₂₃N₇O₂
Masse moléculaire:525.56

Stockage:

Please store the product under the recommended conditions in the Certificate of Analysis.

NNRT-IN-17 Chemical Structure

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Pureté et documentation
Références
Calculators
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target

^[1]

HIV-1 Reverse Transcriptase

0.095 μM (IC₅₀)

HIV-1 Reverse Transcriptase

0.0049 μM (EC₅₀)

Voir tous les produits spécifiques à Isoform HIV :

Cellular Effect

Cell Line	Type	Value	Description	References
MT4	EC50	0.0049 μM	Antiviral activity against wild-type HIV-1 IIIB infected MT-4 cells measured as protection against HIV-1-induced cytopathicity by MTT assay. Antiviral activity against wild-type HIV-1 IIIB infected MT-4 cells measured as protection against HIV-1-induced cytopathicity by MTT assay.	42556026
MT4	EC50	0.13 μM	Antiviral activity against K103N/Y181C (RES056) double mutant HIV-1 infected MT-4 cells measured as protection against HIV-1-induced cytopathicity by MTT assay. Antiviral activity against K103N/Y181C (RES056) double mutant HIV-1 infected MT-4 cells measured as protection against HIV-1-induced cytopathicity by MTT assay.	42556026
MT4	CC₅₀	1.97 μM	Cytotoxicity against mock-infected MT-4 cells assessed by MTT assay. Cytotoxicity against mock-infected MT-4 cells assessed by MTT assay.	42556026
MT4	EC50	0.0099 μM	Antiviral activity against L100I NNRTI-resistant mutant HIV-1 infected MT-4 cells measured as protection against HIV-1-induced cytopathicity by MTT assay. Antiviral activity against L100I NNRTI-resistant mutant HIV-1 infected MT-4 cells measured as protection against HIV-1-induced cytopathicity by MTT assay.	42556026
MT4	EC50	0.0035 μM	Antiviral activity against K103N NNRTI-resistant mutant HIV-1 infected MT-4 cells measured as protection against HIV-1-induced cytopathicity by MTT assay. Antiviral activity against K103N NNRTI-resistant mutant HIV-1 infected MT-4 cells measured as protection against HIV-1-induced cytopathicity by MTT assay.	42556026
MT4	EC50	0.017 μM	Antiviral activity against Y181C NNRTI-resistant mutant HIV-1 infected MT-4 cells measured as protection against HIV-1-induced cytopathicity by MTT assay. Antiviral activity against Y181C NNRTI-resistant mutant HIV-1 infected MT-4 cells measured as protection against HIV-1-induced cytopathicity by MTT assay.	42556026
MT4	EC50	0.077 μM	Antiviral activity against Y188L NNRTI-resistant mutant HIV-1 infected MT-4 cells measured as protection against HIV-1-induced cytopathicity by MTT assay. Antiviral activity against Y188L NNRTI-resistant mutant HIV-1 infected MT-4 cells measured as protection against HIV-1-induced cytopathicity by MTT assay.	42556026
MT4	EC50	0.0078 μM	Antiviral activity against E138K NNRTI-resistant mutant HIV-1 infected MT-4 cells measured as protection against HIV-1-induced cytopathicity by MTT assay. Antiviral activity against E138K NNRTI-resistant mutant HIV-1 infected MT-4 cells measured as protection against HIV-1-induced cytopathicity by MTT assay.	42556026
MT4	EC50	0.093 μM	Antiviral activity against F227L/V106A NNRTI-resistant mutant HIV-1 infected MT-4 cells measured as protection against HIV-1-induced cytopathicity by MTT assay. Antiviral activity against F227L/V106A NNRTI-resistant mutant HIV-1 infected MT-4 cells measured as protection against HIV-1-induced cytopathicity by MTT assay.	42556026

In Vitro

NNRT-IN-17 (COMPOUND 19) exhibits potent antiviral activity against wild-type HIV-1 IIIB and broad activity across a panel of NNRTI-resistant HIV-1 strains when tested in MT-4 cells, with a 0.0049 μM EC₅₀ against wild-type HIV-1 and a 0.0035 μM EC₅₀ against the prevalent K103N mutant^[1].
NNRT-IN-17 (COMPOUND 19) potently inhibits wild-type HIV-1 reverse transcriptase in a cell-free biochemical assay, with an IC₅₀ of 0.095 μM, confirming direct molecular targeting of the viral enzyme^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

Research Protocol for Infectious Diseases

Chemical Information

Masse moléculaire 525.56
Formule C₃₁H₂₃N₇O₂
SMILES

O=C(NCC1=CC=NC=C1)C#CC2=C(OC3=C(C)C=C(/C=C/C#N)C=C3C)N=C(NC4=CC=C(C#N)C=C4)N=C2
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureté et documentation

Instruction de manipulation (2659 KB)

Références

[1]. Ji X, et al. Rational design of dual-site NNRTIs based on 2,4,5-trisubstituted pyrimidine scaffold for potent inhibition of resistant HIV-1. European journal of medicinal chemistry. 2026 Nov 15;318:119193.

Calculators

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Obtenir un devis En stock

Other size

Obtenir un devis